PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB-eath 1-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMB Each 1-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB cortex number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

| | Complete if Known | \mathfrak{L} |
|------------------------|----------------------|----------------|
| Application Number | 09/724,961 | Z |
| Filing Date | November 28, 2001 | TH |
| First Named Inventor | Schenk, Dale B. | |
| Group Art Unit | 1771-1647 | 8 |
| Examiner Name | -Unassigned AXICHOLS | 75 |
| Attorney Docket Number | 15270J-004752US | 3 |

| | | | | U.S. Patent Docume | R . | | Pages, Columns, Lines, |
|-------|--------------------|--------------|--------------------------|--------------------|-----------------------------------|--|---|
| | Examin Initials | | Cite No. ¹ | Number Kind Cod | Martine of Parentees of Applicant | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | X | $a_{\rm II}$ | 196 | 6,150,091 | Pandolfo et al. | 11-21-2000 | |
| יי כ | 3 | \mathbb{Z} | 1 | 6,057,367 | Stamler et al. | 05-02-2000 | |
| | | | 2 | 5,958,883 | Snow | 09-28-1999 | |
| | 2001 | | 3 | 5,955,317 | Suzuki et al. | 09-21-1999 | |
| EP 2 | 2001 | Q. | 4 | 5,955,079 | Mond et al. | 09-21-1999 | |
| | | | 5 | 5,877,399 | Hsiao et al. | 03-02-1999 | |
| | 19. | 7 | 6 | 5,869,093 | Welner et al. | 02-09-1999 | |
| APT * | DEN | | 7 | 5,869,054 | Weiner et al. | 02-09-1999 | |
| · · | | | 8 | 5,854,204 | Findeis et al. | 12-29-1998 | |
| | | | 9 | 5,851,996 | Kline | 12-22-1998 | |
| | | | 10 | 5,849,298 | Weiner et al. | 12-15-1998 | |
| | | | 11 | 5,837,473 | Maggio e al. | 11-17-1998 | |
| | | | 12 | 5,786,180 | Konig et al. | 07-28-1998 | |
| | 7 | | 207 | 5,780,587 | Potter | 07-14-1998 | |
| | | | 13 | 5,753,624 | McMichael et al. | 05-19-1998 | |
| | | | 14 | 5,750,349 | Suzuki et al. | 05-12-1998 | |
| | | | 197 | 5,744,368 | Goldgaber et al. | 04-28-1998 | |
| | | _ | 211 | 5,736,142 | Sette et al. | 04-07-1998 | A |
| | · 1 | | 15 | 5,733,547 | Weiner et al. | 03-31-1998 | |
| | | | 16 | 5,688,651 | Solomon | 11-18-1997 | |
| | | | 17 | 5,679,348 | Nesburn et al. | 10-21-1997 | |
| | | | 18 | 5,845,820 | Hafler et al. | 07-08-1997 | |
| | | | 19 | 5,641,474 | Haffer et al. | 06-24-1997 | |
| | | _ | 20 | 5,641,473 | Hafter et al. | 06-24-1997 | |
| | | | 21 | 5,612,486 | McConlogue et al. | 03-18-1997 | |
| | | | 22 | 5,605,811 | Seubert et al. | 02-25-1997 | · |
| | | | 23 | 5,585,100 | Mond et al. | 12-17-1996 | |
| | | | 24 | 5,571,500 | Hafter et al. | 11-05-1998 | |
| | | _ | 25 | 5,571,499 | Hafler et al. | 11-05-1998 | |
| | | | 175 | 5,441,870 | Seubert, et al. | 08-15-1995 | |
| · | | | 28 | 5,434,170 | Andrulis, Jr. | 07-18-1995 | |
| | | | 27 | 5,387,742 | Cordell | 02-07-1995 | , |
| | 1 | _ | 181 | 5,270,165 | Van Nostrand et al. | 12-14-1993 | / |
| | 12 | | 28 | 5,231,000 | Majocha et al. | 07-27-1993 | |

| Examiner | Date | 12 (-) (- |
|-----------|------------|------------|
| Signature | Considered | 19-5-702 |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number, ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002. OMB 0951-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | (woo as many | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | ٠. |
|-------|--------------|------|---|----|
| Chast | | _ | | - |
| | | | | |

| ļ | e required to respond to a collection | or knorregion unless (compares a valio Olivie cor | MOTOGRAPH TOR |
|---|---------------------------------------|---|---------------|
| | | Complete If Known | Ω |
| | Application Number | 09/724,961 | Z |
| | Filing Date | November 28, 2001 | - 17 |
| | First Named Inventor | Schenk, Dale B. | |
| | Group Art Unit | 1771 /644 | 핑 |
| | Examiner Name | Unassigned NICHOLS | 2 |
| | Attorney Docket Number | 15270J-004752US | 8 |

| \overline{o} | | Θ | 0 | 29 | 5,220,013 | Ponte et al. | 06-15-1993 | ~ |
|----------------|---|--------------|---------------|-----|-----------|-----------------|------------|---|
| _ | ~ | \mathbf{X} | | 30 | 5,208,036 | Eppstein et al. | 05-04-1993 | |
| | | 4 | \mathcal{T} | 31 | 5,192,753 | McGeer et al. | 03-09-1993 | |
| , | | | ST. | 32 | 5,187,153 | Cordell et al. | 02-16-93 | |
| • | O | , , | 1 | 33 | 5,057,540 | Kensil et al. | 10-15-1991 | |
| | | a . | \mathcal{F} | 198 | 5,004,697 | Pardridge | 04-0201991 | |
| | d | 33 | 0 | 34 | 4,666,829 | Glenner et al. | 05-19-1987 | |
| . OH | _ | _ | _ | | | | | |

| | | | | FOREIGI | N PATENT DOCU | IMENTS | | |
|-----------------------|--------------|-------------------------|---------------------------------------|--|---|--|--|----------|
| Examiner Initials* | Cite No.1 | For Office ³ | eign Patent Do Number ⁴ | Cument Kind Code ⁸ (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Τ° |
| (2) | 35 | EΡ | 911 036 | A2 | | 04-28-1999 | | |
| -01- | 36 | EP | 868 918 | A2 | | 10-07-1998 | | -0- |
| | 37 | EP | 863 211 | A1 | | 09-09-1998 | | 0 |
| | 38 | EP | 845 270 | A1 | | 08-03-1998 | | |
| | 39 | EP | 782 859 | A1 | | 07-09-1997 | | 0 |
| | 40 | EP | 683 234 | A1 | | 11-22-1995 | | -0- |
| 1 | 41 | EP | 666 080 | A1 | | 08-09-1995 | | 0 |
| | 42 | EP | 652 962 | B1 | | 12-16-1998 | - KISA | þ |
| | 43 | EP | 639 081 | B1 | | 11-03-1999 | | SUP |
| | 44 | EP | 613 007 | A2 | | 08-31-1994 | C | ₹ |
| | 45 | EP | 594 607 | B1 | | 08-27-1997 | - UCP 9 | <u>,</u> |
| | 46 | EP | 561 087 | B1 | | 08-04-1999 | | - (00) |
| | 47 | EP | 526 511 | B1 | | 05-28-1997 | | -0 |
| | 48 | EP | 506 785 | B1 | | 03-15-2000 | | 7/10 |
| 1 | 49 | EP | 451 700 | A1 | | 10-15-1991 | | TO T |
| | 50 | EP | 440 619 | B1 | | 01-24-1996 | | |
| | 51 | ΕP | 359 783 | B1 | | 11-29-1995 | | -0- |
| | 52 | EP | 276 723 | B1 | | 12-08-1993 | , | 8 |
| | 187 | EP | 783 104 | A1 | | 07-09-1997 | | 0- |
| | 199 | PCT | 00/77178 | A1 | | 12-21-2000 | | -8 |
| | 188 | PCT | 00/43049 | A1 | | 07-27-2000 | | -6 |
| 1 | 53 | PCT | 99/60024 | A1 | | 11-25-1999 | | 6 |
| | 54 | PCT | 99/60021 | A2 | | 11-15-1999 | | -0 |
| 1 | 55 | PCT | 99/58564 | A1 | | 11-18-1999 | | 6 |
| 1 | 56 | PCT | 99/06066 | A2 | | 02-11-1999 | | d |
| XX | 57 | PCT | 99/27949 | A1 | | 06-10-1999 | | - 0 |

| Signature Considered Considered | Examiner Signature | Date Considered | 12-8-02 |
|---------------------------------|--------------------|--------------------|---------|
|---------------------------------|--------------------|--------------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, ⁶ Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449A/PTO

Sheet

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMENCE
prespond to a colocion of information unless it contains the contains contai Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it conteins a valid OMB control rules.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

+

(use as many sheets as necessary)

of | 11

| | Complete if Known | \overline{c} |
|------------------------|---------------------|----------------|
| Application Number | 09/724,961 | |
| Filing Date | November 28, 2001 | ī |
| First Named Inventor | Schenk, Dale B. | 3 |
| Group Art Unit | 4771-1647 | 9 |
| Examiner Name | Unassigned-XJC1+025 | 707 |
| Attorney Docket Number | 15270 I-004752LIS | - 62 |

| | | ^ − | | | | | | | | |
|----------------|---------------|----------------|-----|-----|----------|------|---|------------|------------------|----------|
| OIPE | To the second | abla | 58 | PCT | 99/27944 | A1 | | 06-10-1999 | -0- | l |
| /0 | 45X 1 | ਹ | 59 | PCT | 99/27911 | A1 | | 06-10-1999 | | l |
| / • | 31 | | 203 | PCT | 99/00150 | A2 | | 01-07-1999 | | |
| (SEP 2 4 2 | ו. ומו | | 60 | PCT | 98/44955 | A1 | | 10-15-1998 | 0 | • |
| | | | 61 | PCT | 98/07850 | A2 | | 02-26-1998 | | l |
| (Z | .6 | \neg | 202 | PCT | 97/21728 | A1 . | | 06-19-1997 | | _ |
| PART A TRADE | RE | | 62 | PCT | 97/17613 | A1 | | 05-15-1997 | | į |
| THADE | | | 63 | PCT | 96/39176 | A1 | | 12-12-1996 | | . |
| | | \neg | 208 | PCT | 96/28471 | A1_ | | 09-19-1998 | S (-) | N. |
| | | | 64 | PCT | 96/25435 | A1_ | | 08-22-1996 | 7-9- | |
| | | | 65 | PCT | 96/18900 | A1 | | 06-20-1996 | [48] | L |
| | | | 66 | PCT | 95/31996 | A1 | | 11-30-1995 | -02-0 | 1 |
| | | | 200 | PCT | 95/12815 | A1 | | 05-11-1995 | 7 €, | ~4 |
| | | | 67 | PCT | 95/11994 | A1_ | | 05-04-1995 | | ٠. |
| | | | 68 | PCT | 95/11311 | A1 | | 04-27-1995 | -6-/ | 0 |
| | | \Box | 69 | PCT | 95/05853 | A1 | | 03-02-1995 | | • |
| | | \Box | 70 | PCT | 95/04151 | A2 | | 02-09-1995 | 0 | 7 |
| | | | 201 | PCT | 94/28412 | A1 | | 12-08-1994 | -0- | l |
| | | | 71 | PCT | 94/03815 | A1 | | 02-17-1994 | | ! |
| | | | 72 | PCT | 94/01772 | A1 | | 01-20-1994 | | |
| | |] | 73 | PCT | 93/21950 | A1 | | 11-11-1993 | 0 | |
| | | | 74 | PCT | 93/16724 | A1 | | 09-02-1993 | | l |
| | | | 75 | PCT | 93/15760 | A1 | | 08-19-1993 | 0 | |
| | | | 76 | PCT | 93/14200 | A1 | | 07-22-1993 | <u> </u> | l |
| | | | 205 | PCT | 93/04194 | A1 | | 03-04-1993 | -0- | ı |
| | | | 77 | PCT | 93/02189 | A1 | | 02-04-1993 | - | I |
| | | _ | 78 | PCT | 92/13069 | A1 | | 08-06-1992 | -0 | |
| | | _ | 79 | PCT | 92/06708 | A1 | | 04-30-1992 | <u>-B-</u> | |
| | | | 80 | PCT | 92/06187 | A1 | | 04-16-1992 | 0 | |
| | L1 | _ | 81 | PCT | 91/19810 | A1 | | 12-26-1991 | | ~ |
| | | | 82 | PCT | 91/15819 | A1 | | 11-14-1991 | | |
| | | | 83 | PCT | 91/12816 | A1 | 7 | 09-05-1991 | <u></u> | l |
| | | \Box | 84 | PCT | 91/08760 | A1 | | 06-27-1991 | | i |
| | | \sqcup | 85 | PCT | 90/12871 | A1 | | 11-01-1990 | - | |
| | | Ш | 86 | PCT | 90/12870 | A1 | | 11-01-1990 | -0. | |
| | | Н | 87 | PCT | 89/01343 | A1 | | 02-23-1989 | 0- | |
| | | Ш | 88 | PCT | 89/06242 | A1 | | 07-13-1989 | | |
| • | | | 89 | PCT | 89/06689 | A1 | | 07-27-1989 | | |
| | | $oldsymbol{L}$ | 90 | PCT | 89/03687 | A1 | | 05-05-1989 | | |

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

| Please | type a | olus | sian | (+) | inside | this | box |
|--------|--------|------|------|-----|--------|------|-----|

|+|

PTO/SBJOEA (08-00)

Approved for use through 10/31/2002. OMEDS 51-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB of the United States.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/724,961 November 28, 2001 **Filing Date** First Named Inventor Schenk, Dale B. Group Art Unit 1771-/6/7 Examiner Name

(use as many sheets as necessary)

Sheet of

| Common Hama | Criassigned MICI |
|------------------------|------------------|
| Attorney Docket Number | 15270J-004752US |

| | | | | | | |
|----|----|-----|-----------|----|----------------|-----|
| 4 | 91 | PCT | 88/10120 | A1 | 12-29-1988 | - 0 |
| | 92 | GB | 2 220 211 | A | 01-04-1990 | |
| 07 | 93 | GB | 2 335 192 | A | 09-15-1999 | -8- |



TC 1700

Examiner Signature

Date Considered R-5-0a

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet of | 11

| | Complete if Known | |
|----------------------|--------------------|--|
| Application Number | 09/724,961 | 15 |
| Filing Date | November 28,2001 | K |
| First Named Inventor | Schenk, Dale B. | 350. |
| Group Art Unit | 4774 1642 | - |
| Examiner Name | Unassigned (C) (C) | 76.5 |
| | | |

| Examiner Name | | <u> </u> |
|------------------------|-----------------|----------|
| Attorney Docket Number | 15270J-004752US | |
| | | |

| | | | OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS | | ľ |
|------------|----------|--------------|---|--------|---|
| \int_{I} | Examiner | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² | |
| _ | OS 8 | 94 | ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995). | 0 | ŀ |
| | 2017 6 | 95 | Associated Press, "Immune cells may promote Alzehimer's, a study finds," The Boston Globe (4/13/95). | 0 | |
| END | AFT OFFI | 96 | BAUER et al., "Interleukin-6 and α-2-macroglobulin Indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991). | -0- | ŀ |
| | | 204 | BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor- Transgenic Mice," <u>Eur. J. Immunol</u> , 29:345-354 (1999). | 空 | ŀ |
| | | 212 | BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheomer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992). | E CHON | ł |
| | | 176 | BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000). | 雪 | ł |
| | | 97 | BLASS, John P., "Immunologic Treatment of Alzhelmer's Disease," New England J. Medicing, 341(22):1694 (1999). | 000000 | ŀ |
| | | 98 | BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Blophys. Res. Comm.</u> , 171(2):890-897 (1990). | 8 | ŀ |
| | | 99 | BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presentlin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997). | 0 | |
| | | 100 | BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin, Genet Develop.</u> , 3: 102-109 (1993). | -8- | ŀ |
| | | 101 | BRICE et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg, Psychiatry</u> , 56:112-115 (1993). | -8- | ŀ |
| Ţ | | 102 | CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," <u>Soc.</u> <u>Neurosci, Abstracts</u> , 19:513.7 (1993). | 0 | |
| | | 213 | CHEN et al. *An Antibody to β Amytold Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types,* Neuroscience Letters 125:223-228 (1991). | 0 | |
| | | 214 | DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA. 10.1073/pnas.151261398</u> (2001). | 0 | |
| | | 103 | DUFF et al., "Mouse model made," <u>Nature</u> , 373: 478-477 (1995). | -8- | |
| [| TO | 104 | ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol.</u> <u>Sciences</u> , 59:341-347 (1983). | 0 | ŀ |

| Examiner | | Date | |
|-----------|------|------------|---------|
| Signature | July | Considered | 17-5-02 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | (uso as man | y saloots as | nocessery, |
|-------|-------------|--------------|------------|
| Sheet | 6 | of | 11 |

| Complete if Known | | | | | |
|-------------------------------|-----------------------|--|--|--|--|
| Application Number 09/724,961 | | | | | |
| Filing Date | November 28,2001 | | | | |
| First Named Inventor | Schenk, Dale B. | | | | |
| Group Art Unit | 777+ 1647 | | | | |
| Examiner Name | Unassigned PICHOLS UX | | | | |

| Sheet | 6 | of 11 | Attorney Docket Number | 15270J-004752US | ŽŽ | | |
|--|-----|--|---|---|------------|--|--|
| THE STATE OF THE S | 105 | | Processing of the β-amyloid precursor protein carr binant C-terminal mutation," <u>Neuroscience Letter</u> | | 7 | | |
| 8 | 106 | FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobjology of Aging, 17(5):809-815 (1996). | | | | | |
| 2007 5 | 107 | FISHER et al., "Expressi | on of the amyloid precursor protein gene in mous 1782 (1991). | e oocytes and embryos," PNAS, 88:1779- | -0 | | |
| 1/82 (1991). 108 FLANDERS et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 1569 (1995). | | | | Uzheimer's disease," <u>Neurology,</u> 45:1561- | 0 | | |
| | 210 | FRIEDLAND et al., ""De | evelopment of an anti-Aβ monoclonal antibody for Alzheimer's disease," Mol. Neurology, 9:107- | | 저 | | |
| | 109 | GAMES et al., "Alzhe | imer-type neuropathology in transgenic mice over protein," <u>Nature</u> , 373(6514): 523-527 (| | THE SECOND | | |
| | 215 | GAMES et al., "Prevent | ion and Reduction of AD-type Pathology in PDAP the New York Academy of Science 920:274 | | NA | | |
| T T | | _ | | | محرا | | |

| | | protein, <u>Nature</u> , 373(6514): 523-527 (1995). | À |
|----|-----|---|------------|
| | 215 | GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with AB ₁₋₄₂ ." <u>Annals of the New York Academy of Science</u> 920:274-84 (2000). | BNES |
| | 110 | GANDY et al., "Amyloidogenesis in Alzhelmer's disease: some possible therapeutic opportunities," <u>TiPS</u> , 13:108-113 (1992). | |
| | 111 | GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.,</u> 177:1181-1186 (1993). | 400/2900 p |
| | 112 | GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998). | υф |
| | 113 | GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994). | a |
| | 114 | GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984). | 0 |
| | 115 | GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991). | ۔ |
| | 116 | GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996). | 0 |
| | 190 | GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7018 (1995). | 0 |
| | 117 | GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," Vaccine, 15(12/13): 1341-1343 (1997). | 0 |
| | 118 | HAGA et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993). | 0 |
| 10 | 119 | HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997). | 0 |
| | | <u></u> | |

| Examiner Signatur | Sur | Date Considered | 12-5-02 |
|----------------------|-----|--------------------|---------|
| | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 vl

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

+

(use as many sheets as necessary)

| | , | | |
|-------|---|------|----|
| Sheet | 7 | of | 11 |

| Complete if Known | | | | |
|------------------------|--------------------|--|--|--|
| Application Number | 09/724,961 | | | |
| Filing Date | November 28,2001 | | | |
| First Named Inventor | Schenk, Dale B. | | | |
| Group Art Unit | 1774 WHT "465 | | | |
| Examiner Name | Unassigned MICHOLS | | | |
| Attorney Docket Number | 15270J-004752US | | | |

| | | | | | <u>~ (0 -</u> 5), |
|-----------|--------|---------------|-----|---|-------------------|
| 01 | PES | \mathcal{I} | 120 | HARDY, "Amyloid, the presentiins and Alzheimer's disease," TINS, 20(4): 154-159 (1997). | |
| | | 3 | 121 | HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996). | 14 |
| \SEP 2 | | Ž. | 193 | HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enclase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Act</u> a. 1158:120-128 (1993). | |
| BAT & TRA | DEMARY | | 177 | HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," <u>Science</u> , 289:375 (2000). | |
| | | | 122 | HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amytoid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996). | FF 1 |
| | | | 123 | HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. NeuroImmunology</u> , 52:147-152 (1994). | 180912 |
| | | | 124 | HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine. 333(19):1283-1284 (1995). | 290 |
| | | | 125 | TAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J.</u> <u>Neuroimmunology</u> , 24:173-182 (1989). | - |
| | | | 192 | WATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron, 13:45-53 (1994). | 0 |
| | | | 126 | JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-218 (1982). | 0 |
| | | | 216 | JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> 138:373-378 (1991). | -0- |
| | | | 127 | KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992). | -0- |
| , | | | 183 | KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996). | 0 |
| | | | 128 | KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991). | -0 |
| | | | 195 | KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl- Terminus of the βΑ4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996). | 0 |
| | | | 129 | LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Corlex During Alzhelmer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993). | 0 |
| | | | 130 | LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990). | -0 |
| | 7 | | 131 | LANNFELT et al., "Alzhelmer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993). | 0 |
| | | | | · · · · · · · · · · · · · · · · · · · | |

| | Δ | | | |
|-----------------------|-----|--------------------|----|-------|
| Examiner Signature | Sim | Date Consid r d | 12 | -5-02 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

STATEMENT BY APPLICANT

| | (ago oo man) | 0.00.0 | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
|-------|--------------|--------|---|
| Sheet | 8 | of | 11 |

'SEP 2

Examiner

| | Complete if Known |
|------------------------|---|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1774- VOFT 100 100 100 100 100 100 100 100 100 10 |
| Examiner Name | Unassigned MICHOLS |
| Attorney Docket Number | 15270J-004752US |

| | 132 | Mice," Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 3-28, 1999). | (80) | | | |
|----------|-----|--|--------------|--|--|--|
| 2007 | 133 | LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced In Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997). | | | | |
| MAK OFFI | 134 | LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991). | <u>E</u> | | | |
| | 218 | MAJOCHA et al., *Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy,* The J. of Nuclear Med. 33:2184-2189 (1992). | 9 | | | |
| | 217 | MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985). | - | | | |
| | 135 | MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro, Encap.</u> , 14(2): 197-210 (1997). | 40 | | | |
| | 136 | MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," <u>Nature</u> , 374:647-650 (1995). | 48 | | | |
| | 137 | MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). | -8 | | | |
| | 206 | MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chern.,</u> 287(24):17082-17088 (1992). | • | | | |
| | 191 | MURPHY et al., "Development of a Monocional Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994). | | | | |
| | 138 | NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," Am. J. Epidemiol, 145(11): 959-989 (June 1, 1997). | ₽ | | | |
| | 139 | New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94). | 0 | | | |
| | 140 | PARESCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996). | | | | |
| | 141 | PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers." <u>Eur. J.</u> <u>Immunol.</u> , 25: 3521-3524 (1995). | a (| | | |
| | 142 | PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 864 (1994). | | | | |
| 95 | 143 | QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991). | 0 | | | |
| | 144 | PASO-VA, Grant application # 1 R43 AGL 57.45, Q1, (publication data unknown). The KACL | - | | | |
| 95 | 145 | RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998). | - · | | | |

LEMERE et al., "Mucosal Administration of Aß Peptide Decreases Cerebral Amyloid Burden In Pd-App Tanganic

| oignature 232000 | Oorisidered | 18 0 | 00 | _ |
|---|-----------------------------|---------------------|------------------------------|----|
| EXAMINER: Initial if reference considered, whether or not citation is | in conformance with MPEP 60 | 9. Draw line throug | h citation if not in conform | ar |
| and not considered. Include copy of this form with next communicatio | n to applicant. | • | | |

Date

12-8-02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Transfation is attached.

Substitute for form 1449A/PTO

| | (USG as many si | 3110013 03 11000331 | | |
|-------|-----------------|---------------------|----|--|
| Shoot | 0 | 1 01 | 44 | |

| | Complete if Known |
|------------------------|--------------------|
| Application Number | 09/724,961 |
| Filing Date | November 28,2001 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1774-1647 |
| Examiner Name | Unassigned DICHOLS |
| Attorney Docket Number | 15270J-004752US |

| 146 | ROGERS et al., "Complement activation by β-amyfold in Alzheimer Disease," PNAS, 89:1-5 (1997). | 820 |
|-----|--|---|
| 147 | ROSSOR et al., "Alzheimer's Disease Families with Amytold Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993). | TO. |
| 209 | RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). | 4 |
| 189 | SAIDO et al., "Spatial Resolution of Fodrin Proteotysis in Postischemic Brain," <u>J. Biol. Chem.,</u> 268(33):25239-25243 (1993). | - |
| 194 | SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 289(21):15253-15257 (1994). | 0 |
| 178 | SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," <u>J. Med. Chem.,</u> 38(21):4141–4154 (1995). | 10 |
| 148 | SCHENK et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999). | -0 |
| 149 | SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000). | 4 |
| 150 | SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol</u> , 53(5): 438-447 (1994). | þ |
| 151 | SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 18(10): 403–409 (1993). | |
| 152 | SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease," <u>Scientific American</u> , pgs. 88-78 (November, 1991). | 0 |
| 153 | SELKOE, Dennis J., "In the Beginning," <u>Nature</u> , 354:432-433 (1991). | 0 |
| 154 | SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991). | 0 |
| 155 | SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:930-831 (1997). | |
| 156 | SEUBERT et al., "isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," <u>Nature,</u> 359: 325-327 (1992). | æ |
| 157 | SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992). | æ |
| 158 | SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997). | 0 |
| 159 | SOLOMON et al., "Disaggregation of Alzheimer β-amytoid by site-directed mAb," PNAS, 94:4109-4112 (1997). | 0 |
| | 147 209 189 194 178 148 149 150 151 152 153 154 155 156 157 158 | ROSSOR et al., "Alzheimer's Disease Families with Amytold Precursor Protein Mutations," Annals of New York Academy of Sciences. 695:198-202 (1993). RUDINGER, "Characteristics of the Amino Adds as Components of a Pepide Hormone Sequence," in Peptide Hormones. J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1983). SAIDO et al., "Spatial Resolution of the Primary β-Amytologenic Process Induced in Postischemic Hippocampus," J. Biol. Chem., 268(21):15283-15287 (1994). SCHENK et al., "Therapeutic Approaches Related to Amytold-β Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1985). SCHENK et al., "Immunization with amytold-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999). SCHENK et al., "Immunization with amytold-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999). SELKOE, D.J., "Imaging Alzheimer's Amytold," Nat Biotech., 18:823-824 (2000). SELKOE, "Physiological production of the β-amytold protein and the mechanism of Alzheimer's disease," Trands in Neurosciences, 16(10): 403-409 (1993). SELKOE, Dennis J., "Amytold Protein and Alzheimer's Disease," Scientific American, pgs. 88-78 (November, 1991). SELKOE, Dennis J., "Amytold Protein and Alzheimer's Disease," Scientific American, pgs. 88-78 (November, 1991). SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:830-831 (1997). SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature, 359: 325-327 (1992). SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992). |

| Examiner Signature Date Considered 72-5-02 | | |
|--|--|---------|
| | | 12-5-02 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 vI

¹ Unique citation designation number. 3 Applicant is to place a check mark here if English language Translation is attached.

10

Sheet

of | 11

15270J-004752US

Attorney Docket Number

| Flease type a plus sign (+) Inside this box + SEP 2 Under the Paperwork Reduction Act of 1995, Reportsons | S. Patent and Tra | pproved for use through 10/31/2002. (Idemark Office: U.S. DEPARTMENT C | OF COMMERC | 主 |
|---|----------------------|---|------------|------|
| Substitute for form 1449A/PTO | | Complete if Known | A A | 10 |
| | Application Number | 09/724,961 | æ | ਹਾ |
| INFORMATION DISCLOSURE | Fling Date | November 28,2001 | <u>6</u> | 2001 |
| STATEMENT BY APPLICANT | First Named Inventor | Schenk, Dale B. | 8 |]= |
| | Group Art Unit | 1771- 1647- | <u> </u> |] |
| (use as many sheets as necessary) | Examiner Name | Unassigned-NICHO | us 8 |] ' |

| 80 | 160 | SOLOMON et al., "Monoclonal antibodies inhibit in <i>vitro</i> fibrillar aggregation of the Alzheimer β-amyloid peptide." <u>PNAS</u> , 93:452-455 (1998). | E. | Z |
|----|-------|--|-----|-----|
| | 761 | SOLOMON, A: Pro-Rx (Protein Therapeutics), University of Tetinessee Medical Center (publication dates p. unknown). | 200 | 200 |
| | 162 | SOLOMON, B., "New Approach Towards Fast Induction of Anti p-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biolechnology, Tel-Aviv University, Remet Aviv, Tel-Aviv, Israel (publication of a unknown)." | 4 | |
| 80 | 182 | SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzhelmer's β-amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996). | 6 | 1 |
| | 184 | SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol.</u> <u>Biol. Int.</u> , 43(3):601-611 (1997). | 0 | 4 |
| 70 | 185 | SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996). | 0 | 1 |
| | 186 , | COLOMON et al., Activity of monoclonal ampodies in prevention of in vitro aggregation of their antigens," abstract from Department of Mulecular Microbiology and Biotechnology, TerAnn University, TerAnny Israel (publication data unknown). | T | 6 |
| 5 | 179 | SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996). | 0 | l |
| | 163 | STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malarla", <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997). | T | 1 |
| | 164 | STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997). | 0 | 7 |
| | 165 | TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998). | 4 | Ş |
| | 166 | TRIEB et al., "Is Alzhelmer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994). | 10 | |
| | 167 | VAN GOOL et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994). | -8- | ł |
| | 168 | VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994). | -8 | |
| | 169 | WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994). | - | |
| | 180 | WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998). | -0- | ŀ |
| | 170 | WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Blotech., 18:868-824 (2000). | 4 | ł |
| 9 | 171 | WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ- Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994). | 0 | |

| | Date Consider d 12-5-02 |
|--|-------------------------|
|--|-------------------------|

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box Under the Paperwork Reduction Act of 1991 PADEMAR Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

> of 11

Sheet

PTO/SB/08B (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB gone of number.

Complete if Known Application Number 09/724,961 **Filing Date** November 28,2001 Schenk, Dale B. First Named Inventor

4774- 1647 Group Art Unit Unassigned PICHOU Examiner Name 15270J-004752US **Attorney Docket Number**

| 76 | 172 | WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Opin, Neurobiol., 7: 695-700 (1997). |
|----|-----|---|
| | 219 | WONG et al., "Neuritic Plaques and Cerebrovascular Amylold in Alzheimer Disease are Antigenically Related," Proc. Natl. Acad. Sci. USA, 82:8729-8732 (1985). |
| 96 | 173 | WOOD et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," PNAS, 94: 1550-1555 (1997). |
| | 174 | Human-Immunology & Cancer Program brochure; from The University of Tenessee Medical Centerr Graduate Schools of Medicine, Knowille, Tennessee (publication date unknown). |
| | | SEP 2 |
| | | |
| | | TC 1700 |
| | | |

| $\overline{}$ | | |
|-----------------------|-----|--|
| Examiner Signature | Dun | |

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3169033 vl

| | #1 | 1 |
|---|----|---|
| • | | |

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB segtral multipler. Substitute for form 1449A/PTO Complete if Known **Application Number** 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Schenk, Dale B. Group Art Unit 1647 (use as many sheets as necessary) Examiner Name Turner, Sharen Sheet of 6 Attorney Docket Number 15270J-004752US

| | | | | U.S. PATENT DOCUM | MENTS | | ∮ ~ |
|------------|------|-----------------|----|--|---------------------------|--|-------------|
| Examiner | Cite | U.S. Patent Doo | | | Date of Publication of | Pages, Columns, Lines, Where Relevant | 12 |
| Initials • | No.1 | Number (if kno | | Name of Patentee or Applicant of Cited Document | Cited Document MM-DD-YYYY | Passages or Relevant Figures Appear | QZ. |
| 760_ | 267 | 6,294,171 | B2 | McMichael | 09-25-2001 | | , a |
| 9 | 234 | 6,284,221 | B1 | Schenk, et al. | 09-04-2001 | RF | # // /r |
| | 300 | 2001/0018053 | A1 | McMichael | 08-30-2001 | | 147 A C |
| | 230 | 6,262,335 | B1 | Hsiao et al. | 07-17-2001 | SEP | 1/ |
| | 231 | 6,114,133 | | Seubert et al. | 09-05-2000 | | 2002 |
| | 221 | 5,989,566 | | Cobb et al. | 11-23-1999 | TECHNOL | 1 W |
| | 284 | 5,231,170 | | Averback | 07-27-1993 | TUHLEN | F. 1600/ |
| 1 | 242 | | | Challfour et al. | N/A | | |
| | 282 | 80/160,687 | | Chain | N/A- | | |
| | 205 | - 00/104,001 | | Holtzman et al. | TV/A | | TW - |
| | 500 | 60/186,295 | | Rasmussen et al. | N/A' | | لج [|
| T^{-} | -299 | 60/254,485 | | Heltamon et al. | N/A | | ١Ŵ |
| | 907 | 60/254,498 | | Holtzman et al | N/A | | 1/- |
| 1~ | 289- | 09/441,140 | | - Colomon et al. | N/A | | 1.7 |

| | | | | FOREIG | N PATENT DOCU | MENTS | | |
|-----------------------|--------------|---------------------|---------------------|--------------------------------------|---|----------------------------|--|----|
| Examiner Initials* | 0.11 | For | eign Patent Do | cument | Name of Delegates | Date of Publication of | Pages, Columns, Lines, | |
| | Cite No.1 | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | Name of Patentee or Applicant of Cited Document | Cited Document MM-DD-YYYY | Where Relevant Passages or Relevant Figures Appear | T° |
| | 243 | PCT | 01/39796 | A2 | | 08-07-2001 | - | |
| | 298 | PCT | 01/42308 | A2 | | 08-14-2001 | | |
| | 301 | PCT | 01/82284 | A2 | | 03-01-2000 | | |
| | 294 | PCT | 01/62801 | A2 | | 08-30-2001 | | |
| | 240 | PCT | 00/43039 | A1 | | 07-27-2000 | | |
| 0 | 227 | PCT | 95/11008 | A2 | | 04-27-1995 | | |

| Examiner Signature | Slew | Date Considered | 12-5-02 |
|-----------------------|------|--------------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, DC 20231.

PA 3244120 v1

PA3242256 v2 PA 3147648 v21

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

| _ | _ |
|---|---|
| | |
| | |
| | |
| | |
| | |

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 14498/PTO **Application Number** 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT **First Named Inventor** Schenk, Dale B. Group Art Unit 1647 (use as many sheets as necessary) **Examiner Name** Turner, Oharon Sheet of 6 Attorney Docket Number 15270J-004752US

| | | OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS | |
|---------|--------------|--|---|
| xaminer | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | 7 |
| 85 | 228 | BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <u>J. Mol.Biol.</u> , 225(4): 1075-1093 (1992). | |
| | 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET. | |
| | 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-4148 (1992). | 7 |
| | 224 | Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at . http://www.ida.gov/eber/vaccine/thimerosal.htm, lect-updated May 16, 2002. | _ |
| 31 | 266 | CHAPMAN, PAUL F., "Model behavior," <u>Nature</u> , 408:915-916 (2000). | |
| | 222 | Chemical Abstract-database, Abstract-of-Injection of Determine Their Safety-in-User Int Biologicals, "Chemical Abstract database. (Publication date unknown.) Main Ma | |
| 为 | 302 | CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Armyloid β-Peptide by Microglial Cells," J. Blol. Chem., 274(45):32301-32308 (1999). | |
| | 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000). | |
| | 286 | CORDELL, B., *\$-Amyloid formation as a potential therapeutic target for Alzheimer's disease,* Ann. Rev. Pharmacol, Ioxicol., 34:69-89 (1994). | |
| | 287 | COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993). | |
| र्र | 293 | DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Scl., 63:2121-2131 (1998). | |
| | 220 - | Dialog/Derwerk, 703078ctr of WPI-Ace No. 1997-054438/199706; Stable Vacciner compans. comprise a macrocyclic lactone, a milbernycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water soll organic solvent and saline or water. Derwent: WRI database(Publication date: unknown) | |
| Ø | 288 | DUMERY et al., 'B-Amyloid protein aggregation; its implication in the physiopathology of Alzhelmer's disease,' Pathol. Biol., 49:72-85 (2001). | |
| 75 | 225 | Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002). | - |

| Examiner Signature | Date Considered | 12-5-02 |
|--------------------|--------------------|---------|

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1 PA3242256 v2 PA 3147648 v21

+

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0851-0031 U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete If Known Application Number 09/724,961 INFORMATION DISCLOSURE November 28, 2000 **Filing Date** STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor Group Art Unit 1647 NICHOZZ (use as many sheets as necessary) Turner, Sharon **Examiner Name** Sheet 3 of 6 15270J-004752US **Attorney Docket Number**

| Examiner | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T2 |
|----------|--------------|---|----|
| 70 | 228 | Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002). | |
| | 289 | ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm, Sci.</u> , 22:2-3 (2001). | _ |
| | 246 | FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001). | |
| | 247 | FRENKEL et al., "Immunization against Alzhelmer's β-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000). | |
| | 248 | FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmunology, 88:85-90 (1998). | |
| | 245 | FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-armyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of NeuroImmunology</u> , 95:136-142 (1999). | |
| | 244 | FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 106:23-31 (2000). | - |
| | 249 | FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). | _ |
| | 251 | GARDAELLA et al., "Intact Alzheimer amyloid precursor prolein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Blochem, Bloohys, Res. Comm.</u> , 173:1292-1298 (1990). | |
| | 252 | GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzhelmer's disease," Neurobiology of Aging, 20:75-79 (1999). | |
| | 253 | GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzhelmer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998). | |
| | 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998). | |
| | 237 | GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949). | |
| | 254 | GRUBECK-LOEBENSTEIN, et al., *Immunization with β-armyloid: could T-cell activation have a harmful effect?*, TINS, 23:114 (2000). | _ |
| 2 | 241 | HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992). | _ |

| | | | _ |
|-----------------------|--------------------|---------|---|
| Examiner Signature | Date Considered | 12-5-02 | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1 PA3242256 v2 PA 3147648 v 21

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number, ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known **Application Number** 09/724,961 INFORMATION DISCLOSURE **Filing Date** November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor **Group Art Unit** 1647 Tomer Shaven MICHOLS (use as many sheets as necessary) Examiner Name Sheet of 6 15270J-004752US 4 Attorney Docket Number

| | | OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS | |
|------------------------|--------------|--|------------------------|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published. | Τ2 |
| 100° | 255 | HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease." <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995). | T |
| | 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993). | בנוו לבוז בוז וסיטומים |
| | 236 | HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 201:81-69 (1991). | - 1 |
| | 256 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:448-449 (1987). | |
| | 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997). | |
| | 258 | KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995). | - |
| | 259 | LANSBURY, PETER T., "Inhibition of amytoid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Obs. in Chemical Biology</u> , 1:260-267 (1997). | |
| | 260 | LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328–331 (2000). | _ |
| | 261 | MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994). | _ |
| | 263 | MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Aβ42(43)." <u>Annals of Neurology</u> , 40:149-156 (1996). | _ |
| | 262 | MANN, et al., "The extent of armyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995). | _ |
| | 264 | McGeer, et al., "Immunohietochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992). | _ |
| | 238 | MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-186 (1998). | _ |
| | 265 | Mena, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol</u> , 89:50-58 (1995). | |
| M | 233 | MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989). | |

| | Date \sqrt{Q} | 5-02 |
|--|-----------------|------|
|--|-----------------|------|

EXAMINER; initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 vl PA3242256 v2 PA 3147648 v 21

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



of

Sheet

PTO/SB/08A (08-00)

15270J-004752US

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete If Known Application Number 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Schenk, Dale B. 1647 **Group Art Unit** (use as many sheets as necessary) Examiner Name Tarrier, Sharon MICHOCA

Attorney Docket Number

| | | OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS | |
|------------------------|--------------|--|----|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T2 |
| M | 250 | NAKAMURA et al., "Histopethological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995). | |
| | 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1985). | |
| | 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amytoldosis in cynomolgus monkeys," <u>J. of Med. Primatology.</u> 27:244-252 (1998). | _ |
| | 235 | NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys. Acts.</u> , 104:480-486 (1965). | |
| | 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem, Biophys. Res. Comm.</u> , 148:307-313 (1987). | _ |
| | 232 | PETERSON, et al., * Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine- Derived Monoclonal Antibodies,* <u>Laboratory Animal Science</u> , 46(1):8-14 (1998). | |
| 95 | 289 | PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amytoid precursor protein," <u>J. of Neuroscience Res.</u> , 48:709-719 (1996). | |
| | 304 | Disease (publication #1 R49 AGI 5740-01-(non-18dacted version), Immunotherapy of Alzheimer's Disease (publication data unknown) | |
| 3 | 279 | SAITO et al., "Vector-mediated delivery of ¹²⁵ l-labeled β-amyloid peptide Ab ¹⁻⁴⁰ through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ ¹⁻⁴⁰ vector complex, " <u>PNAS USA</u> , 92:10227-10231 (1995). | |
| 9 | 278 | SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti-β-protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991). | |
| | 277 | SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997). | |
| | 270 | SCHENK, et al., "β-peptide immunization," <u>Arch. Nuerol.</u> , 57:934-936 (2000). | |
| | 271 | ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116- 117 (1999). | |
| | 272 | SZENDREI, et al., "The effects of aspartic acid-bond isomerization on <i>in vitro</i> properties of the amyloid β-peptide as modeled with <i>N</i> -terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-298 (1996). | _ |
| 95 | 273 | THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000). | _ |

| Examiner Signature | Date Considered | 12-5-02 |
|-----------------------|--------------------|---------|
| | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, DC 20231.

PA 3244120 v1 PA3242256 v2 PA 3147648 v 21

¹ Unique citation designation number: 2 Applicant is to place a check mark here if English language Translation is attached.



of

Sheet

6

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

15270J-004752US

| Under the Paperwork Reduction Act of 1995, no persons | are required to respond to a collection | of information unless it contains a valid OMB control number. |
|---|---|---|
| Substitute for form 1449A/PTO | | Complete if Known |
| | Application Number | 09/724,961 |
| INFORMATION DISCLOSURE | Filing Date | November 28, 2000 |
| STATEMENT BY APPLICANT | First Named Inventor | Schenk, Dale B. |
| | Group Art Unit | 1647 |
| (use as many sheets as necessary) | Examiner Name | Furner, Sharon NICHULS |

Attorney Docket Number

| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 2 |
|------------------------|--------------|---|-----|
| 80 | 276 | TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996). | |
| 60 | 274 | WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). | |
| - | 223 = | Wisconsin Alumni Research Poundation, "Injection of Newborn Mice with Seven Chemical Adjuvants-to-Help' Determine Their Safety in Use in Biologicals", 4.6 Govt. Res. Devalop-Rep.: 70(24): 88. (Publication-date) unknown) | _ |
| 56 | 275 | WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997). | |
| | 292 | YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998). | |
| 76 | 290 | YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001). | |

| Examiner Signature | Date Considered | 125-02 |
|-----------------------|--------------------|--------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3244120 v1

PA3242256 v2 PA 3147648 v 21

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/OLA (10-01)
Approved for use through 10/51/8002, OMB 0881-0031*
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1955, no persons are required to respond to a projection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 09/724,981 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Dale B, Schenk Art Unit (uze as many sheels as necessary) 🐬 🦠 Examiner Name Sharon Turner 10 of 13 Alterney Docket Number 15270J-004752US Sheet.

| | | <u> </u> | ATENT DOCUMEN | TS <u> </u> | <u> </u> | |
|------------------------|-------------|--|--------------------------------|--|---|---------------------------|
| | | Document Number | | · | 7 | |
| Examiner's Initials | Cite No. | Number Kind Code ² (<i>if known</i>) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, C Lines, V Relevant f or Rel Figures | Vhere assages event |
| S | 326 | 2002/0136718 A1- | 09-26-2002 | Raso | | |
| | 325 | 2001/0102261 A1 | 08-01-2002 | Raso | 7.4 | |
| | 308 | 6,417,178 B1 | 07-09-2002 | Klunk-et al. | | |
| | 267 | 6,294,171 B2 | 09-25-2001 | McMichael | | |
| | 234_ | 6,284,221 B1 | 09-04-2001 | Schenk, et al. | <u></u> | 7.5 |
| | 300_ | 2001/0018053 A1 | 08-30-2001 | McMichael | | |
| | 230_ | 6,262,335 B1- | 07-17-2001 | Hsiao et al. | | |
| | 305 | 09/724,842 | 11-28-2000 | Chalifour et al. | | .,. |
| | 231 | 6,114,133 | 09-05-2000 | Saubert et al. | | |
| | 221 | 5,989,566 | 11-23-1999 | Cobb et al. | • | |
| | 283 | 09/441,140 - | 11-16-1999 | Solomon et al | | |
| | 321 | 5,837,672 - | 11-17-1998 | Schenk et al. | | |
| 4 | 320 | 5,593,846~ | 01-14-1997 | Schenk et al. | L | |
| 3 | 284 | 5,231,170 | . 07-27-1993 | Averback . | | |
| | 242 | 60/168,504 | - NA | Chalifour et al. | | |
| | 282 | 60/169,687 | N/A | - Chaln | | - 6 |
| | 205 | 80/184,601 | > | Holizman et al. | | |
| | 206 | 80/254,465 | N/A | Holtzman et al. | | , |
| | 297 | 80/254,408 | N/A | Holtzman et al. | - | |
| | 299- | 00/186,295 | N/A* | Rasmussen et al. | - | |

| | | ····· | | |
|---|-----------------------|-------------|----------------------|--|
| 1 | Examinar | 7 44 ** 0 . | Date // oc/ > -2 | |
| 1 | Examiner Signature | (a-1/1/20X | Considered 412912004 | |
| | | | 1/2/100 | |
| | | | | |

EXAMINER: Initial if reference considered, whether or not obtain is in conformance with MPSP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique clastion designation number (optional). ⁹ Kind Codes of U.S. Patent Documents at <u>www.uspio.gov</u> or MPEP 901.04. ⁹ Enter Office that issued the document, by the two-letter code (WIPC) Standard S.T.3). * For Japanese patent documents, the indication of the year of the reign of the Emparer must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S.T. 18 if possible. ⁸ Applicant is to place a check mark here if English language Transferton is ettached.

Burden Hour Statement: This form is settingted to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents Inc. 20234

Received from < 16503262422 > at 2/18/03 9:04:00 PM (Eastern Standard Time)

Complete if Known

PTO/BB/03.A ([0-01)

Approved for use through 10/31/2002. QMB 0651-0081

U.S. Palent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1865, no persons are resided to respond to a collection of information unless a combine a year of UMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) 13 of

| -Application aumeer | 09/724,961 | |
|------------------------|-------------------------|---|
| Filing Date | November 28, 2000 | |
| First Named Inventor | Dale 8. Schenk | |
| Art Unit | 1647 | |
| Examiner Namo , | Sharen Turner - NICHOLS | v |
| Attorney Docket Number | 15270 L004752US | • |

| | | | FORE | IGN PATENT | DOCUMENTS | • | <u> </u> | | |
|-----------------------|--------------|--------------------------------|------------|----------------------|--------------------------------|---|--|-------------------------|----------------|
| Examiner initials* | Cite No.1 | Forn Country Code ³ | Number | Kind Code (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages Column Lines, Where Releva Passage Releva Figure Appea | es, nt e or nt | т ^в |
| دوري | 294 | WO | 01/62801 | A2 | 08-30-2001 | - | | \exists | Ţ |
| 1 | 301 | Wo | 01/82284 - | A2 | 03-01-2000 | | | 7 | |
| | 298 | wo | . 01/42306 | A2 | 08-14-2001 | | | | |
| | 243 | wo | . 01/39796 | A2 | 06-07-2001 | | | \rightarrow | |
| | 322 | WO | 00/72880 | A2, A3 | 12-07-2000 | | | <u>.=-</u> | _ |
| | 323 | WO | 00/72876 | A2, A3 | 12-07-2000 | | | | |
| | 324 | ·wo | 00/72870 | A1 | 12-07-2000 | | | | |
| - | 240 | WO | 00/43039 | A1 | 07-27-2000 | | | | Ē |
| 1 | 331 | wo | 99/06545 | A2 | 11-02-1999 | | | | |
| Car | 227 | WO | 95/11008 | -A2 | 04-27-1995 | | | | |

| | | <u>.</u> | | |
|-----------------------|------|------------------|---------|------|
| Examiner Signature | Miss | Date Consider | w 4/29/ | 2003 |

EXAMINER: Initial if reference canadidated, whether or not citation is in conformance with MPEP 600. Draw fine through citation if not in conformance and not considered, include copy of this form with next convinuintation to applicant.

Applicant's unique offston designation number (optional), 2 Kind Codes of U.S. Patent Documents at www.yerno.gov or UPEP 901.04. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.S). 2 For Japanese patent documents, the indication of the year of the emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document. under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Committedings for

.....

| PTC/SB/02B (1 | | |
|---|------|--|
| FACTORVED (1) | ~~;; | |
| oproved for use through 10/31/2002. OMB 0651- | 2031 | |
| | | |

Under the Pepsyark Reduction Act of 1995, no persons are required to respond to a colorion of information unless it contains a valid CMB control number

Substitute for form 1449B/PTO Complete If Known Application Number 09/724,981 INFORMATION DISCLOSURE Filing Date November 26, 2000 STATEMENT BY APPLICANT First Named Inventor Dale B. Schenk Art Unit 1847 (use as many sheets as necessary) Examiner Name Sheron Turner Attorney Docket Number 15270J-004752US

| ' | ОТН | ER PRIOR ART NON PATENT LITERATURE DOCUMENTS | | |
|---------------|----------------|--|----------|---------|
| Examiner | Cite | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 2 | [- |
| دىوى | 228 | BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amylold Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J. Mol.Biol., 225(4): 1075-1093 (1992). | , r | 2/2 |
| | 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging;" Reuters, April 20, 2001 7:56 PM ET. | | 7 |
| V | 327 | CAMERON, "Recent Advances in Transgenic Technology," Molecular Biotechnology, 7:253-265 (1997). | | 200 |
| (0) | 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharm.</u> , 15:414A-414B (1992). | 1 | ÖQ |
| | 224 | Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thirmerosal in Vaccines (Mercury in Plasma Derived St. Products), web site contents found at . | -0 | (A) |
| | <u>ن</u> جث | http://www.fda.gov/cber/vaccine/tinimerosal.htm, last updated May 18, 2002. | ,, | 5 |
| 9 | ~ 268 5 | CHAPMAN, PAUL F., "Model behavior," Nature, 408:915-916 (2006). | <u> </u> | 6 |
| $(C_{1})^{2}$ | 222 | Chemical Abstract detabase, Abstract of Injection of Newborn Miss. With Seven Chemical Adjuvants to Help Determine Their Safety in Use | 1); | JO 201 |
| مربرب | •• | in Blologicals," Chemical Abstract database. (Publication date- unknown.) | | Ü |

Examiner Date Signature Considered

TEXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 609, Draw line through citation if not in communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to pieco a check mark here it English tenguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Find will vary depending upon the needs of the includual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND PEBS OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Partents, Washington, DC 20231.

PA 3284621 V1

c

PTO/SB/08B (19-01)

Approved for use through 10/31/2002, OMB 0861-0031

U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a callection of information unitses it contains a valid CMB control number.

Substitute for form 1449B/PTO Complete If Known **Application Number** 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Dale B. Schenk Art Unit 1647 (use as many sheets as necessary) Examiner Name Sheron Turner 15270J-004752US Attorney Docket Number

| GN 307 | | CHEN, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature, 408(6815):975-9 (2000). | |
|--------------|---|---|--------|
| | 332 CHEN, et al., "Neurodegenerative Alzheimer-like pàthology in PDAPE 717V→F transgenic mice," <u>Progress in Brain Research</u> , Van Leeuwei et al. Eds, 117:327-337 (1998). | | |
| | 302 | CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzhelmer's Amyloid β-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999). | |
| | 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000). | |
| | 333 | CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset. Parkinson's disease: Implications for pathogenesis and therapy." PNAS, 97(2):571-576 (2000) | - 1 5 |
| | 286 | CORDELL; B., "A-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994). | _ |
| | 287 | COSTA et.al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993). | |
| S 293 | | DALY; et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998). | d (45) |

| | | | <i></i> | i_ |
|-----------------------|------|-----------------|-----------|----|
| Examiner Signature | Milo | Date Considered | 4/29/2003 | 2 |

EXAMINER: initial if reference consistent, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copyler this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is altoched

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark. Office, Washington, DC 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 v1

Sheet

PTO/SE/0FB (10-01)
Approved for use through 10/51/2002, OMB 0651-0031

Street Torner

-15270J-004752US

| Underthe Paperwork Reduction Act of 1985, no persons | U.S. Patent and Tradi a see required to respond to a collection of | emark Office: U.S. DEPARTMENT OF COM A information unique it contains a valid OMB contro | MERCE |
|--|---|---|--------|
| Substitute for form 1449B/PTO | | Complete If Known | |
| | Application Number | 09/724,961 | |
| INFORMATION DISCLOSURE | Piling Date | November 28, 2000 - | (1. |
| STATEMENT BY APPLICANT | First Named Inventor | Dale B. Schenk | |
| | Art Unit . | 1847 - | \neg |
| . (use as many abbels as necessary) | Examiner Name | Sharpe Turner A) CHEN | .3 |

Attorney Docket Number

Dialog/Derwent, Abstract of WPI ACC No: 4997-054430/199706: Clable vaccine compana. - comprise a macrocyclic lectone, a milbemydin, anavennectin, an antigen, a dispersing agent, an adjuvant, a water sel: organic solvent and ealine or water, Derwant File 351: Derwant WRI database: (Publication date unknown.) < 318 DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology, 57(5):801-5 (2001). 288 DUMERY et al., '8-Amyloid protein aggregation; its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001). 225 Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release, (1/28/2002). 226 Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002) 289 ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm. 6cl., 22:2-3 (2001). 328 FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" Alzheimer's and Parkinson's Diseases, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). 246 FRENKEL et al., "Generation of auto-antibodies_towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001). FRENKEL et al., "High affinity binding of monoclonal antibodies to the-245 sequential epitope EFRH of \$\beta\$-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999).

| Examiner Signature | Miles . | Date Considered | 4/29/03 | |
|--------------------|---------|-----------------|---------|--|

EXAMINER: Initial if reference-considered, whether or not oldation to in conformance with MPEP 609. Draw line through citation if not in conformand not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Traderical Office, Washington, DC 20281, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3284621 VI

¹ Applicants unique obston designation number (optional). 1 Applicant is to place a check mark here if English language Translation is extern

· i

·PI.

ø.,

PTO/E2/08 (1)-01)

Aparoved for use through 10/31/2002, CMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to respond to a conscious of information unjess it contains a velid CMB control number

| Substitute for form 1448B/PTO | Complete If Known | | | |
|---------------------------------------|-------------------------------------|-----------------------|--|--|
| INFORMATION BIGGI OFFICE | Application Number | 09/724,961 | | |
| INFORMATION DISCLOSURE | Filing Date | November 28, 2000 | | |
| STATEMENT BY APPLICANT | First Named Inventor Dale B, Schenk | | | |
| T | Art Unit | 1647 | | |
| (use as many sheets as necessary) *** | Examiner Name | Sharon Turner NICHOLS | | |
| Sheet 6 of 13 | Attorney Docket Number | 15270J-004752U8 | | |

| <u> </u> | | | L |
|----------|-----|--|------|
| جي | 247 | FRENKEL et al., "Immunization against Alzheimer's 8-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000). | |
| | | FRENKEL et al., "N-terminal EFRH sequence of Alzhelmer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998). | .: |
| ., | 244 | FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 108:23-31 (2000). | · .: |
| - | 249 | FRIEDLAND, et al., "NeuroImaging of Vessel Amyloid in Alzhelmer's Disease," In <u>Cerebrovascular Pathology in Alzhelmer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). | |
| | 251 | GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem, Biophys. Res. Comm., 173:1292-1298 (1990). | - |
| * | 252 | GEDDES, "N-terminus truncated \$\beta\-armyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: dietinot roles in the pathogenesis of Alzhelmer's disease," Neurobiology of Aging, 20:75-79 (1999). | |
| | 253 | GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998). | 2 P |
| 3 | 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of sometic mutants with hallmarks of antibody affinity maturation," [mmunology, 93:145-153 (1998). | |

| | | | <u> </u> | | |
|-------------------------|-------|--------------------|----------|-------|--|
| Examinar C Signature | Miles | Date Considered | 4/ | 29/03 | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique existion designation number (optional). * Applicant le to place a check mark here it English language Translation is estached,

Burden Hour Stremment: This form le settimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO; Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 V1

710

PTO/SR/OED (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE:
ad to respond to a cofcolion of information unless it contains a velid CAS control mymber:

Uniter the Peperwork Reduction Act of 1995, no persons are require Substitute for form 1449B/PTO Complete if Known Application Number 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Dale B. Schenk First Named Inventor Art Unit 1847 (use as many sheets as naceszary) Examiner Name Sharon Turner NICHOUS of 13 152701-004752U9 Sheet Attorney Docket Number

| | JW | - 237 | GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949). | |
|------|--------|-------|--|-----|
| | | 254 | GRUBECK-LOEBENSTEIN, et al., "Immunization with Bamyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000). | •, |
| : .; | 1 | 241 | HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(8393):322-5 (1992). | - |
| | | 255 | HARIGAYA, et al., "Modified amyloid & protein ending at 42 or 40 with different solubility accumulates in the brain of Alzhelmer's disease," Biochem, Biophys, Res. Comm., 211:1015-1022 (1995). | |
| | | 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993). | |
| | | 236 | HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in puffers of pH 7.4," Eur. J. Biochem., 201:61-69 (1991). | |
| | | 255 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-\$\text{\text{protein}} = \text{monoclonal antibody," Lab. Invest., 57:448-449 (1987)} | . , |
| | 1 | 308 | JANUS; et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzhaimer's disease. Nature. 408(6815):979-82 (2000). | |
| | ري | 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997). | |
| Ex | aminer | | 611. Date 4/29/02 | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not cansidered. Include appropriate the form with next communication to applicant.

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Tradement Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284621 v1

Signature

¹ Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SBUSE (10-01)
Approved for use through 10/31/2002, OMB 0561-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1985, no persone are required to respond to a collection of information unless a collection unless a collection of information unless a collection unless a collection of information unless a collection of information unless a collection unless a co

Bubsilists for form 1449B/PTO Complete If Known Application Number 09/724,981 INFORMATION DISCLOSURE November 28, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor Dele 9. Schenk Art Unit = 1647 (use as many sheets as necessary) Examiner Name Sharon Turner CHOL 15270J-004752US of 13 Attorney Docket Number Sheet 3

| | | | • | 1 |
|-----|-----|---|----------|----------|
| CO | 334 | JOBLING and HOLMES, "Analysis of structure and function of the subunit of cholera toxin by the use of site-directed mutagenesis, Molecular Microbiology, 5(7):1755-1767 (1991). | | |
| | 258 | KIDA, et al., "Early amyloid-β deposits show different immunore to the amino- and carboxy-terminal regions of b-peptide in Alzhe disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 19 108 (1995). | imer's | |
| | 259 | LANSBURY, PETER T., "Inhibition of amyloid formation: a strate delay the onset of Aizhelmer's disease," Curr. Ops. in Chemical Biology, 1:260-287 (1997). | | |
| | 260 | LEMERE, et al., "Nasal A\$ treatment induces anti-A\$ antibody production and decreases cerebral amyloid burden in PD-APP rannals of the NY Acad. Sci., 920:328-331 (2000). | nice," | |
| | 261 | MAK, et al., "Polycionals to b-amyloid (1-42) identify most plaquivascular deposits in Alzheimer cortex, but not striatum," <u>Brain</u> <u>Research</u> , 667:138-142 (1994). | bns e | . – |
| AC | 263 | MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome linked Alzheimer's disease; Predominance of Aβ ₄₂₍₄₈₎ ," Annals of Neurology, 40:149-158 (1996). | | <u>`</u> |
| | 262 | MANN, et al., "The extent of amyloid deposition in brain in patter Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 198:105-108 (1995) | nts with | 1 (5) |
| (De | 335 | MASLIAH et al., "B-Amyloid peptides enhance o-synuclein accumulation and neuronal deficits in a transgenic mouse mode Alzheimer's disease and Parkinson's disease," PNAS, 98(21):12 12250 (2001). | | 9 |

| Examiner Signature | a Wilas | Date Considered | 4/29/ | 03 |
|-----------------------|---------|--------------------|-------|----|

EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, includercopy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time well vary depending upon the nebds of the individual case. Any comments on the amount of time you are required to complete this form chould be sent to the Chief information Officer, U.S. Patent and Trademark Officer, Washington, OC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, OC 20231.

PA 3284821 v1

^{*} Applicant's unique citation designation number (optional). * Applicant is to place a chack mark hero if English language Translation is etlached

| | - | |
|--|---|--|
| | | |

: C.

PTC/S9/03B (10-01)
Approved for use through 10/31/2002, OMB 0651-0061
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless & contains a valid CMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT.

(use as many sheets as necessary)

| | Complete it known | L |
|----------------------|--------------------------|---|
| Application Number | 09/724,981 | Γ |
| Pillng Date | November 28, 2000 | |
| First Named Inventor | Dale B. Schenk | ` |
| Art Unit | 1647 | Γ |
| Descriper North | Shows Turner A 11 CALONS | Ε |

15270J-004752U8 Attorney Docket Number

| | | | | | _ |
|------------|---------|-----|--|------------------------------------|------|
| 2 | ر ال | 309 | MATTSON, Cellular actions of beta-amyloid precursor soluble and fibrillogenic derivatives. Physiol Rev. 77(4 (1997). | protein and its. 1081-132 | |
| | | 284 | MCGEER, et al., "Immunohistochemical localization of precursor protein sequences in Alzheimer and normal light and electron microscopy," J. of Neuroscience Res (1992). | brain tissue by | |
| - | | 238 | MCNEAL et al., "Stimulation of local immunity and protintramuscular immunization with triple- or double-layers particles and QS-21," Virology, 243:158-166 (1998). | | |
| : | | 265 | MENA, et al., "Monitoring pathological assembly of tau proteins in Alzheimer's disease," Acta Neuropathol., 89 | | · - |
| т а | | 310 | MERLUZZI, et al. Humanized antibodies as potential d therapeutic use. Adv Clin Path. 4(2):77-85 (2000). | rugs for | 1 |
| | | 311 | MORGAN, et al. A bete peptide vaccination prevents n animal model of Alzheimer's disease. Nature, 408(681 | | 7 |
| | | 233 | MORRIS, et al., "The Consortium to Establish a registr Disease (CERAD)," <u>Neurology</u> , 39:1159-65 (1989). | y for Alzheimer's | 1 (1 |
| | 9 | 250 | NAKAMURA et al., "Histopathological studies on senile cerebral amyloid angiopathy in aged cynomologus mor Anim., 43:711-718 (1995). | | - |
| Ck | کې | 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal amylold β protein (Aβ) subtypes (Aβ40 and Aβ42(43) described plaques and amyloid angiopathy in brains of age monkeys," Neuroscience Letters, 201.151-154 (1995). | ifferentiate Abijn d cynomolgus | , |
| | | | | | |

| | |
|-----------------------|---------|
| Examiner Signature | 4/29/03 |

EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation, a not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This fam is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Ally comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Parent and Trademark. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284821 V1

¹ Applicants unique citation dealgration number (optional). 2 Applicant to to place a check much horo if English and glassy transported

PTO/SE/DAB (10-01)
Approved for use through 10/61/2002, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
b report to a collection of hittorief or unless it contains a wall CMS covering interest

| | DINGS INC PROGRACK PAGE | DIGITAL OF 1994 III BENDAN II | a ladring in leibouri and conscious | Altri Harry Let 1000 | CONTRACTOR OF ANY COMPACT NO. | LIMITION |
|----|-------------------------------|-------------------------------|-------------------------------------|----------------------|-------------------------------|----------|
| [| Substitute for form 1440B/PTO | , | | Complete If | Known | |
| ١. | · NICODALATION OIG | OL COURT | Application Number | 09/724,961 | | |
| | INFORMATION DIS | | Filing Date | November | 28, 2000 | |
| ٠. | STATEMENT BY A | PPLICANT | First Named Inventor | Dale B. Sc | henk | |
| ĺ | - | , | Art Unit | 1647 | | |
| 1 | (use as many sheets as | necessary) | Examiner Name | Sharon Tu | mer. NICHOE | 3 |
| 7 | Sheet 10 of | 13 | Altorney Docket Number | 15270J-00 | | |
| | - | • | | - | - | \top |

| | C | Gg | 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomologus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998). |
|----|----------|----|-----------------|---|
| | | | 235 | NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Blochim. Bjophys. Acts</u> , 104:480-486 (1985). |
| | | | 329 | NIEMANN, "Transgenic farm animals get off the ground;" <u>Transgenic</u> Research 7:73-75 (1998). |
| ≀j | /u- | | 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Blochem. Blophys. Res. Comm., 146:307-313 (1987). |
| | | • | 336 | PERUTZ et al., "Amyloid fibers are water-filed nanotubes," PNAS, 99(8):5591-5595 (2002). |
| • | | / | 232 | PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Munne-Derived Monoclonal Antibodies," Laboratory Animal Science, 48(1):8-14 (1996). |
| | CI | کر | ··269 | PHILIPPE, et al. "Generation of a monocional antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996). |
| | ~ | | -304 | RASO, V.A., Grant application # 1 R43 AGI 5746-01 (mon-redacted |
| | •. | ٠. | | version), "Immunetherapy of Alzhelmer's Disease" (publication date unknown). |
| | <u>C</u> | ک | 279 | SAITO et al., "Vector-mediated delivery of 12 labeled \$-amyloid peptide Ab1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the As1-40 vector complex," PNAS USA, 92:10227-10231 (1995). |
| | Examin | er | | Callin B Date 479/03 |

EXAMINER: Initial if reference considered, whether or not electron is in conformance with MPEP 809, Draw line (through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademan Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Avaisatent Commissioner for Patents, Washington, DC 20231.

PA 3284821 V1

Signature

Applicant's unique citation designation number (optional), Applicant is to place a check mark here if English language Translation is attached

91.

PTC/SB/NB (10-01)
Approved for use through 10/91/2002. ONB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwark Reduction Act of 1905, no parents are required to respond to a collection of information unitage it contains a visid CNB control number.

Attorney Docket Number

Substitute for form 1448B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | Complete If Known | 1 |
|----------------------|----------------------|---|
| Application Number | 09/724,961 | Τ |
| Filing Date | November 28, 2000 | Γ |
| First Named Inventor | Dale B. Schenk | Γ |
| Art Unit | 1647 | |
| Examiner Name | Sharen Tuines NICHOC | 3 |

152701-00475205

| (30 | 278 | SAITOH, N. and K. IMAI, "Immunological analysis of A disease using anti- B-protein monocional antibodies," 60:309-320 (1991), | Azheimers Sapporo Med. J., | , , | |
|-----|-----|---|-------------------------------|--------|--------|
| | 277 | SASAKI et al., "Human chorold plexus is an uniquely in the brain in amyloidosis: a histochemical, immunohisto ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997). | chemical and | •) | |
| | 312 | SCHENK, et al. immunotherapy with beta-amyloid for disease; a new frontier. DNA Cell Biol. 20(11):679-81 | Alzheimers (2001). | - | |
| | 270 | SCHENK, et al., "8-peptide immunization," Arch. Nuen (2000). | ol., 57:934-936 ² | _ | |
| | 313 | SELKOE, The cell biology of beta-amyloid precursor p presentiin in Alzheimer's disease. Trends Cell Biol. 8((1998). | | , , | - |
| | 330 | SIGMUND, "Viewpoint: Are Studies in Genetically Alter Control," <u>Arterioscier Thromb Vasc Biol.</u> , 20:1425-142 | | - - | |
| | 314 | SIGURDSSON, et al. In vivo reversal of amyloid-beta brain. J Neuropathol Exp Neurol. 59(1):11-17 (2000). | esions in rat | | - |
| | 315 | SINHA, et al. Recent advances in the understanding of APP to beta amyloid peptide. Ann N Y Acad Sci. 92 | | | 5 |
| | 337 | SKOLNICK and FETROW, "From genes to protein struction: novel applications of computational approach genomic era," Trends in Biotech, 18(1):34-39 (2000). | | | - |
| ريق | 319 | SMALL, et al. Alzheimer's disease and Abeta toxicity: bottom. Nat Rev Neurosci. 2(8):596-8 (2001). | from top to | 1(1) | - |

| | <u> </u> | | | <u> </u> |
|-----------------------|----------|--------------------|---|----------|
| Examiner Signature | GMMis | Date Considered | 4 | 29/03 |
| | | | | |

EXAMENER: Initial if reference code identity, whether or not citation is in conformance with MPEP 808, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is settinated to take 2.0 hours to complete. Time will vary depending upon the indexidual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradomark Office, Washington, DO 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DO 20231.

PA 3284821 V1

Applicant's unique eliation designation number (optional). Applicant is to piece a check mark here if English leng tage Translation is attached

PTO/SH/ORB (1)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a vetti CMB control number

Form 1448-PRESS Substitute for form 1448B/PTO Complete if Known 09/724,961 Application Number INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Dale B. Schenk First Named Inventor .1647 Art Unit

(use as many sheets as necessary) Daminer Name CHOW CHOW Attorney Docket Number 15270J-004752US **Sheet** 12 of 13

| | | | <u> </u> | ــــــــــــــــــــــــــــــــــــــ |
|----------|-----|---|-----------------|--|
| CN | 316 | SOTO, et al. Beta sheet breaker peptides inhibit fibrillo brain model of amyloidosis: Implications for Alzheime Med. 4(7):822-6 (1998). | | · · |
| | 271 | ST. GEORGE-HYSLOP, PETER H. and DAVID A. WE :Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (| | - - |
| - | 338 | STEIN and JOHNSON, "Lack of Neurodegeneration in Overexpressing Mutant Amyloid Precursor Protein is A Increased Levels of Transthyretin and Activation of Ce Pathways," The Journal of Neuroscience, 22(17):7380 (September 1, 2002). | ssociated with | . (|
| | 272 | SZENDREI, et al., "The effects of aspartic acid-bond in vitro properties of the amyloid &-peptide as modeled decapeptide fragments," Int. J. Peptide Protein Res., 4 (1998). | with N-terminal | |
| | 339 | TENNENT et al., "Serum amyloid P component prevei the amyloid fibrils of Alzhelmer's disease and systemic PNAS, 92:4299-4303 (1995). | | : |
| | 273 | THORSETT, E.D. and L.H. LATIMER, "Therapeutic and Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:3: | | 1, |
| V | 278 | TJERNBERG et al., "Arrest of B-amyloid fibril formation pentapeptide ligand," Journal of Biological Chemistry, (1998). | | |
| | 317 | VEHMAS, et al. beta-Arrylold peptide vaccination resuchanges in serum and brain Abeta-levels in APPswe/Fmice, as detected by SELDI-TOF-based-ProteinChip® DNA-Cell Biol. (11):713 21 (2001). | S1.DeltaE9 | |
| ·- | | | | |

| Examiner Date 4/79/03 | | | · · · · · · · · · · · · · · · · · · · | LL |
|-----------------------|-----------------------|------|---------------------------------------|-------|
| considered | Examiner Signature | Mich | Date Considered .4// | 20103 |

EXAMINER: Initial If retirends considered, whether or not citation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the release of the individual case. Any comments on the amount of time you are required to complete this form should be earl to the Chief Information Officer, U.S. Patent and Trademark Officer, Weshington, DC 20231. DO NOT SEND PRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284621 v1

¹ Applicant's unique citation designation number (optional). S Applicant is to place a check mark here If English language Translation is attached

| Ur | iderthe Pape | nyork Reduction Act of 1995, no | beuscus sus usdrijus: | to respond to a co | lection of info | meter unicu | contains a valu | OMB control |
|-----------------|--------------|---|----------------------------|---------------------------|---|-------------|-----------------|-----------------|
| detitute for fo | | | | | | mplete If | | ·, |
| | | | App | lication Numbe | | 09/724,98 | | |
| | | v disclosuri | B 0-11111 | g Date | | November | 28, 2000 ··· | , |
| TATE | MENT ! | BY APPLICANÎ | Pirel | Named Inven | tor | Dale B. Sc | henk | ،چ |
| •• | | - | Arti | Init | | 1647 | | |
| (use | os meny s | heets as necessary) | Exar | niner Name | , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | Sharon Tu | mer N(| choc |
| heat .13 | 1 2 7 | of 12 | Attor | ney Docket Nu | mber | 152701-00 | 4752US | |
| · | | · | · · · | | | | · · | <u> </u> |
| 130 | 274 | WEINER et al., "I cerebral amyloid Annals of Neurok | burden in a | mouse mo | del of | | | |
| | 223 | WISCONSIN ALL Newborn Miss wi Safety in Use in I | th Seven C Biologicats" | homical Ad , U.S. Govt | juvant | to Holp | Determin | |
| <u>.</u> | 275 | WU, et al., "Drug the primate blood human insulin rec | -brain bard | ler in vivo w | ith a m | onoclon | al entibod | ugh y-to the |
| | 292 | YAMAGUCHI et a protein, possible Acta Neuropathol | y showing (| a disappeai | | | | |
| Ĭ) | 290 | YOUNKIN, "Amyl cognition," Nature | | | | aques e | d Improve | ≱d |
| | · | | . · | • | | | | |
| 2 m 10m | | | ••• | • | | } | | |
| , | • • | | - | | | - "e-" | | |
| | | | - · | •: | •• | • | • | |
| | | | < | Ti. | - | į. | | 1 |
| • | ~ _ | 4. · | | • | | <u> </u> | • | - |
| _ | 4.5 | | _, | - | | | * | - |
| • | | • : | | , , , | ~~~ | | | |
| | | | | | · . | ! | | |
| | | 7 | | Date | 7. | | _ | |

Applicant's unique citation designation number (optional). Applicant is to place a check mark here it English longuage Translation is attached

Burden Hour Statement: This form is exeminated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284821 v1

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
but Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substi | tute for form 1449/PT | 0 | | Complete if Known | | | |
|--------|-----------------------|--------------|---------|------------------------|-------------------|--|--|
| | | | | Application Number | 09/724,961 | | |
| INF | ORMATIO | N DISCL | .OSURE | Filing Date | November 28, 2000 | | |
| STA | ATEMENT I | BY APP | LICANT | First Named Inventor | Schenk, Dale B. | | |
| | | | | Art Unit | 1647 | | |
| | (use as many s | heets as nec | essary) | Examiner Name | Nichols | | |
| Page | 1 | of | 6 | Attorney Docket Number | 15270J-004752US | | |

| | | | U.S. PATENT D | CUMENTS | |
|----------|--------------|---|--------------------------------|--|---|
| Examiner | Cite No.1 | Document Number Number Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| CANS | 360 | 2003/0073655 A1 | 04-17-2003 | Chain | |
| 1. | 370 | 2003/0068325 A1 | 04-10-2003 | Wang | |
| 7 | 378 | 2002/0197258 A1 | 12-26-2003 | Ghanbari et al. | |
| 3 | 366 | 2002/0187157 A1 | 12-12-2002 | Jensen et al. | |
| | 377 | 2002/0168377 A1 | 11-14-2002 | Schaetzl | |
| | 340 | 2002/0162129 A1 | 10-31-2002 | Lannfelt | |
| | 395 | 2002/0160394 A1 | 10-31-2002 | Wu | |
| | 379 | 2002/0132268 A1 | 09-19-2002 | Chang et al. | |
| | 365 | 2002/0133001 A1 | 09-19-2002 | Gefter et al. | |
| | 362 | 2002/0094335 A1 | 07-18-2002 | Chalifour et al. | |
| | 376 | 2002/0086847 | 07-04-2002 | Chain | |
| | 405 | 6,399,314 B1 | 06-04-2002 | Krishnamurthy | |
| | 342 | 2002/0009445 A1 | 01-24-2002 | Du et al. | |
| | 381 | 2001/0021769 A1 | 09-13-2001 | Prusiner | |
| | 401 | 6,284,533 B1 | 09-04-2001 | Thomas | |
| | 345 | 2002/0077288 A1 | 06-21-2001 | Frangione | |
| | 346 | 5,935,927 | 08-10-1999 | Vitek et al. | |
| | 382 | 5,846,533 | 12-08-1998 | Prusiner | |
| | 353 | 5,824,322 | 10-20-1998 | Balasubramanian | |
| | 357 | 5,776,468 B1 | 07-07-1998 | Hauser et al. | |
| | 380 | 5,750,361 | 05-12-1998 | Prusiner et al. | |
| | 373 | 5,721,130 | 02-24-1998 | Seubert et al. | |
| | 356 | 5,622,701 | 04-22-1997 | Berg | |
| 4 | 358 | 5,583,112 B2 | 12-10-1996 | Kensil et al. | |
| 4 | 403 | 5,464,823 | 11-07-1995 | Lehrer et al. | |
| Qy | 402 | 4,713,366 | 12-15-1987 | Stevens | |
| | | | | | |
| _ | | | | | |

| Examiner Signature | allies | Date Considered | 11/6/03 |
|-----------------------|--------|--------------------|---------|
| | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Enter

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.usoto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute or Texa DEM Complete if Known Application Number 09/724,961 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT Schenk, Dale B. First Named Inventor 1647 Art Unit (use as many sheets as necessary) Examiner Name **Nichols** 15270J-004752US Page of Attorney Docket Number

| | | | FO | REIGN PA | TENT DOCUM | ENTS | | |
|-----------------|------|---------------------------|--------------------------|------------------------------|--------------------------------|--------------------------------|--|----|
| xaminer | Cite | Foreign Patent Document | | | | Name of Patentee or | Pages, Columns, Lines, Where Relevant | [· |
| Initials* | No.1 | Country Code ³ | Number ⁴ Kind | Code ^b (if known) | Publication Date MM-DD-YYYY | Applicant of Cited Document | Passages or Relevant Figures Appear | T⁰ |
| | 343 | EP | 1 172 378 | A1 | 01-16-2002 | | | D |
| I | 351 | wo | 02/34878 | A2 | 05-02-2002 | | | - |
| | 352 | wo | 02/34777 | A1 | 05-02-2002 | | | -0 |
| | 341 | wo | 02/03911 | A2 | 04-07-2001 | | | |
| | 344 | wo | 01/90182 | A2 | 11-29-2001 | | | |
| V- | 348 | wo | 01/77167 | A2 | 10-18-2001 | | | |
| رو ر | 383 | wo | 97/10505 | A1 | 03-20-1997 | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | ļ <u></u> | L | | ┞╠ |
| | | | | _ | | | | 무 |
| | j | 1 | | | 1 | 1 | | |

| Examiner Signature | Calling | Date Considered 1/6/03 |
|-----------------------|---------|------------------------|
| | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copylof this form with next communication to applicant.

Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document of the patent document. The file of the patent document is provided by the appropriate symbols as indicated on the document. under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute to CHABELL

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 09/724,961 Filing Date May 26, 2000 First Named Inventor Schenk, Dale B. Art Unit 1647 Examiner Name **Nichols** Attorney Docket Number 15270J-004752US

(use as many sheets as necessary) Page

| | | NON PATENT LITERATURE DOCUMENTS | |
|------------------------|--------------|---|-----|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 2 |
| 00 | 391 | AGUZZI et al., "Prion research: the next frontiers," Nature, 389:795-798 (1997). | |
| | 393 | AKIYAMA et al., "Inflammation and Alzheimer's disease," Neurobiology of Aging, 21:383-421 (2000). | - |
| | 372 | AKIYAMA et al., "Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," Glia, 25:324-331 (1999). | |
| | 404 | BENJAMINI and LESKOWITZ, from <i>IMMUNOLOGY A Short Course</i> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York. | |
| | 349 | CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003). | 1 |
| | 390 | DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," Biochem, J., 320:53-570 (1996). | |
| | 363 | DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?" Trends in Molecular Medicine, 9(3):85-87 (2003). | |
| | 386 | FRATUTSCHY et al., "Effects of Injected Alzheimer β-amyloid cores in rat brain," <u>PNAS</u> , 88:8362-8366 (1991). | |
| | 364 | FURLAN et al., "Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <u>Brain</u> , 126:285-291 (2003). | |
| | 388 | GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," Ann. Rev. Med., 46:57-65 (1995). | |
| 4 | 397 | GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," PNAS, 96:3108-3113 (1999). | |
| COD | 374 | JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," Alzheimer Disease and Associated Disorders, 9(1):47-51, Raven Press, Ltd., New York (1995). | |

| Examiner | / //- // | Date | 11/1/07 |
|-----------|------------|----------|---------------|
| Signature | A / (11/10 | Consider | ed 11/6(0)> |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include cody of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. AUnder the Paperty

Substitute for form 1449/PTO

PTO/SB/08B (04-03)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/724.961 Filing Date May 26, 2000 **First Named Inventor** Schenk, Dale B. Art Unit 1647 **Examiner Name Nichols** 15270J-004752US

(use as many sheets as necessary) Page of Attorney Docket Number

| | | NON PATENT LITERATURE DOCUMENTS | |
|---------------------|--------------|---|-----|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| 00 | 371 | JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β-Amyloid Peptide (1-43) in Transfected 293 Cells," <u>Blochemical and Blophysical Research Communications</u> , 220:710-718 (1996). | |
| | 347 | JORBECK et al., "Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," Infection and Immunity, May:497-502 (1981). | _ |
| | 389 | KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002). | |
| | 367 | MONSONEGO et al., "Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001). | |
| | 359 | MUNCH et al., "Potentional neurotoxic inflammatory response to Aβ vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087. | |
| | 355 | MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York. | _ |
| | 354 | MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany. | |
| | 350 | NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003). | |
| | 398 | PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy, " <u>J. Mol. Med.</u> , 7:703-707 (2001). | |
| | 406 | PAN et al., "Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide," <u>Exp.</u> <u>Biol. Med.</u> , 227(8):609-615 (2002). | |
| 93 | 394 | PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," PNAS, 90:10608-10612 (1993). | |

| Examiner | 1 | 11. | | Date | / | (100 |
|-----------|-------|-------------|-------------|------------|------|------|
| Signature | 1/ _/ | 111 | | Considered | 1117 | 6105 |
| <u> </u> | | | | | | |

EXAMINER: Initial if reference considered, whether or net citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include cody of this form with next communication to applicant.

Applicant's unique distinct designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete. Including gathering, preparing, and surjecting the completed application form to the USPTO. Time will vary depending upon the individual case. According to the application of the user of the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

KIDENIA Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| Page | 5 | of | 1 |
|------|---|----|---|

| | Complete if Known | |
|------------------------|-------------------|---|
| Application Number | 09/724,961 | |
| Filing Date | May 26, 2000 | |
| First Named Inventor | Schenk, Dale B. | |
| Art Unit | 1647 | |
| Examiner Name | Nichols | |
| Attorney Docket Number | 15270.J-004752US | フ |

| | | NON PATENT LITERATURE DOCUMENTS | |
|---------------------|--------------|---|----|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| 430 | 396 | SIGURDSSON et al., "Anti-priori antibodies for prophylaxis following prion exposure in mice," Neurosciences Letters, 336:185-187 (2003). | _ |
| | 384 | SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002). | - |
| 1 | 400 | SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," Neurobiology of Aging, 23:1001-1008 (2002). | |
| | 368 | SIPE, "Amyloidosis," <u>Annu. Rev. Blochem.</u> , 61:947-975 (1992). | |
| | 369 | SPOONER et al., "The generation and characterization of potentially therapeutic A6 antibodies in mice: differences according to strain and immunization protocol," <u>Vaccine</u> , 21:290-297 (2002). | _ |
| | 361 | SU et al., "Intravascular infusions of soluble \$\textit{\textit{B}}\-amylold compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," \textit{Brain Research}, 818:105-107 (1999). | - |
| | 392 | TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival In Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003). | |
| | 399 | TAN et al., "Amyloidosis," Histopathology, 25:403-414 (1994). | |
| | 375 | TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopthy using end-specific antibodies for Aβ40 and Aβ42: immunohistochemical evidence for amyloid β protein," Neuroscience Letters, 2002:77-80 (1995). | - |
| V | 387 | WELDON et al., "Neurotoxicity of Aß Peptide: Confocal Imaging of Cellular Changes Induced by – Amyloid in Rat CNS In Vivo," Society for Neuroscicence Abstracts, 22(Part 1) (1996). | - |
| N | 385 | WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):-574-587 (2002). | |

| | | | | | $\overline{}$ |
|-----------|-------|---------------|--------------|------------|---------------|
| Examiner | - 1/ | \mathcal{L} | Date | 11 1 - | 1 |
| | | | | 111100 | - 1 |
| Signature | / /// | 1112 / / | Considered 1 | 11 //4//) | 1 |
| U.g | | | 0000000 | | |

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includes copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.